|Videos|July 20, 2022
Urology Times 50 Innovations Series: LHRH analogues in prostate cancer
Author(s)Urology Times staff
“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.
Advertisement
As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.
Advertisement
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Lorelei A. Mucci, ScD, MPH, discusses the evolving evidence surrounding diet, physical activity, and other lifestyle factors in prostate cancer care.
Urologists compare ADT plus ARPI doublets and docetaxel triplets in mCSPC, weighing efficacy, safety, cognition, and cost against patient goals.
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
3
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
4
AACU, WOCN Society urge safeguards in Medicare catheter bidding
5